Indication intelligence, analysis and sector perception

Biostage (BSTG) the “spin” is on; NASDAQ issued a continued listing deficiency notice

November 22, 2016 7:57am

MATERIAL events must be disclosed in a timely basis, not the end result - Embellishment SPIN Award is granted!

Biostage had received a continued listing deficiency notice from The NASDAQ Stock Market LLC because its share price has not met the $1.00 minimum closing bid price requirement for 30 consecutive business days [Nasdaq Listing Rule 5450(a)(1)] – WHEN?

NASDAQ has provided BSTG with a 180-day compliance period, until May 17, 2017.

The Bottom Line: Shouldn’t investors been NOTIFIED when the initial letter was received; we all understand that a “grace” period is awarded to comply.

WHY, the event non-report and resulting embroidery?

Anything else hidden away ...?

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

7 hours 52 min ago
RegMed Investors’ (RMi) pre-open: who knows where share pricing goes as the sword of Damocles hangs overhead

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.